Stockbabie NewsFatherMarketNewsMarket Intelligence
MARKETS
Wire · Markets
Markets

Tirzepatide or Wegovy? Novo Nordisk Says Higher Semaglutide Dose Shows Cardiovascular Edge Over Eli Lilly's Tirzepatide

Sep 29, 2026 · 12:54 PM ET· updated 1h ago
Tirzepatide or Wegovy? Novo Nordisk Says Higher Semaglutide Dose Shows Cardiovascular Edge Over Eli Lilly's Tirzepatide

Novo Nordisk reports lower cardiovascular risk for semaglutide over tirzepatide and secures a $2.6 billion licensing deal.

Share
Why It Matters

Novo Nordisk says its weight loss drug semaglutide is safer for the heart than Eli Lilly's tirzepatide. This news helps Novo Nordisk stay ahead in a competitive market where heart safety matters to doctors and patients.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
NVO38.17
-0.55 (-1.41%)
LLY1,180.67
-4.12 (-0.35%)
BMY63.56
-0.33 (-0.51%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.